Ripretinib turns off the switch in GIST

Smith et al. report the design of ripretinib, an investigational tyrosine kinase inhibitor that forces the activation loop of KIT and PDGFRα into an inactive conformation and targets a broad spectrum of KIT and PDGFRα mutants in...